*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below.
|
|
|
Keep an Eye on MDCX (here's why)
|
|
|
|
|
|
Hey Folks,
Here are a few reasons to take a look at Medicus Pharma Ltd. (MDCX)
1. First-Mover Potential: SkinJect is being developed as potentially the first non-surgical alternative to Mohs surgery.
2. Strong Phase 2 Data: Topline Phase 2 results reported on March 5, 2026 showed 73% clinical clearance and 40% histological clearance in the 200µg cohort at Day 57, with a clear separation from the 38% device-only control arm.
3. Accelerated Regulatory Pathway: The FDA has supported the 505(b)(2) regulatory pathway for SkinJect, which could reduce both development timelines and costs compared to a traditional new drug application.
4. Near-Term FDA Catalyst: An end-of-Phase 2 meeting with the FDA is planned for the first half of 2026 to establish the Phase 3 pathway, representing a near-term regulatory catalyst.
5. Dual-Pipeline Upside: The company has a second pipeline asset in Teverelix, a next-generation GnRH antagonist targeting advanced prostate cancer, with FDA clearance already granted for a Phase 2B study.
6. Addressing A Safety Gap: Teverelix addresses a cardiovascular safety gap in the existing prostate cancer treatment landscape, where cardiovascular disease accounts for roughly 30% of all non-cancer deaths in prostate cancer patients.
Anyways...
That's all for now!
Until Next Time,
-ZT Team
|
P.S. Want our text alerts?
Text “ZIPTRADER” to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply)
|
|
|
|
*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below.
|
|
|
|
|
5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA
|
|
This email was sent to punjabsvera@gmail.com
|
|
*SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of Medicus Pharma Ltd. (MDCX) from April 14, 2026 to April 15, 2026. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC on behalf of Medicus Pharma Ltd, to distribute media on YouTube and email/sms from March 1, 2026 to March 5, 2026. ZipTrader has been previously compensated thirty-eight thousand USD by ACH Bank Transfer by TD Media LLC, who received funds from Awareness Consulting Network LLC, who received funds from Razor Pitch Inc, who received funds from Medicus Pharma Ltd, to distribute media via email, SMS, and YouTube for Medicus Pharma Ltd (MDCX) from August 14, 2025 to August 22, 2025. ZipTrader has been compensated thirty-seven thousand five hundred USD by ACH Bank Transfer by TD Media LLC, who received funds from Awareness Consulting Network LLC, to distribute media via email, SMS, and YouTube for Medicus Pharma Ltd (MDCX) from July 8, 2025 to July 10, 2025. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Medicus Pharma Ltd. (MDCX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Medicus Pharma Ltd. (MDCX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Medicus Pharma Ltd. (MDCX), increased trading volume, and possibly an increased share price of Medicus Pharma Ltd. (MDCX), which may or may not be temporary and decrease once the marketing arrangement has ended.
|
|
BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer.
|
|
|
|
|
|
|
|
|
